Bharat Biotech Co-founder Dr Krishna Ella receives award from Johns Hopkins Bloomberg School of Public Health

Published On 2024-05-25 08:25 GMT   |   Update On 2024-05-25 08:25 GMT

Hyderabad: Dr Krishna Ella, the Co-founder and Executive Chairman of Bharat Biotech, has received the esteemed Dean's Medal from the Johns Hopkins Bloomberg School of Public Health.

The award was presented to Dr. Ella by Dean Ellen J. MacKenzie during Bloomberg School’s Convocation Ceremony at Baltimore, Maryland, for his exceptional leadership, enduring vision and contribution to improving public health.

Advertisement

John Hopkins Bloomberg School of Public Health acknowledges Dr. Ella’s pioneering work, remarkable influence, and determination to develop an indigenous, innovative, and safe vaccine focused on global public health, according to a statement by Hyderabad-based Bharat Biotech on Friday.

Also Read:1 in 3 Bharat Biotech Covaxin takers reported adverse events, finds BHU study

This is the school’s highest honour, reserved for outstanding public health researchers and practitioners who demonstrate exceptional leadership in safeguarding and improving public health.

“I acknowledge this medal as a global recognition of India’s scientific excellence, and dedicate this medal to Bharat, which has shown remarkable success by advancing science and R&D, to our exemplary team of scientists, and the results of our strong commitment to the public,” said Krishna Ella on receiving the Dean’s Medal.

His contributions to shaping India’s policies on science, research and innovation made possible the development of vaccines and monoclonal antibodies, including Covaxin, India’s own Covid-19 vaccine.

Under his guidance, Bharat Biotech manufactured the first indigenous rotavirus vaccine (Rotavac), the first WHO-prequalified Typhoid conjugate vaccine (Tybar TCV) and Japanese Encephalitis Vaccine, JENVAC.

Also Read:ICMR distances itself from BHU Covaxin study, calls it poorly designed

During the COVID-19 pandemic, Bharat Biotech developed COVAXIN in a record time, conducting the largest-ever human clinical trials and peer-reviewed by world-leading medical journals.

Tags:    
Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News